Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report

• Main Authors: Gilbert Paul (Author), Rudnick Chad (Author)
• Format: Book
• Published: BMC, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/s12887-021-02618-y; 1471-2431
• Keywords: COVID-19; Vaccination; Newborn; Cord blood; Maternal; Pediatrics; RJ1-570
• Source: BMC Pediatrics, Vol 21, Iss 1, Pp 1-2 (2021)

Abstract Background Maternal vaccination for Influenza and Tetanus, Diphtheria, acellular Pertussis (TDaP) have been well studied in terms of safety and efficacy for protection of the newborn by placental passage of antibodies. Similar newborn protection would be expected after maternal vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). There is a significant and urgent need for research regarding safety and efficacy of vaccination against SARS-CoV-2 during pregnancy. Case presentation A vigorous, healthy, full-term female was born to a COVID-19 naïve mother who had received a single dose of messenger RNA (mRNA) vaccine for SARS-CoV-2 3 weeks prior to delivery. IgG cord blood antibodies were detected to SARS-CoV-2 at the time of birth. Conclusion Here, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.